For comments, suggestions
Created with Raphaël 2.1.0 29.03.2019 Filing date 30.10.2020 Validation fee payment 31.03.2021 (A1) Patent application published 21.07.2024 AGEPI application filing date 31.10.2024 (T2) Translation of the validated European patent 27.06.2025 29.03.2026 Valid until 30.03.2027 Renewal fee to be paid until 29.03.2039 Patent will expire on

Patent in force


(210)Number of the EPO application19722308
(220)Filing date of the EPO application2019.03.29
(80)EPO patent specification publication (B)EPB nr. 20/2024, 2024.05.15
(110)EPO patent number3773593
(11)Number of the documentMD 3773593 T2
(21)Number of the applicatione 2021 0137
(71)Name(s) of applicant(s), code of the countryINCYTE CORPORATION, US;
(72)Name(s) of inventor(s), code of the countryHOWELL Michael D., US;
SMITH Paul, US;
(73)Name(s) of owner(s), code of the countryINCYTE CORPORATION, US;
(54)Title of the inventionTreatment of hidradenitis suppurativa using JAK inhibitors
(13)Kind-of-document code T2
(51)International Patent Classification A61K 31/519 (2006.01.01); A61K 31/4155 (2006.01.01); A61K 31/437 (2006.01.01); A61P 17/10 (2006.01.01); A61K 45/06 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2021.03.31
(49)Date of publication of the translation of the validated European patent specification2024.10.31
(30)Priority201862650600 P, 2018.03.30, US
(74)Patent attorney(Procedură) PARASCA Dumitru, str. Eminescu nr. 40, ap. 13, c/p 28, MD-2012, Chişinău, Republica Moldova
(86)International applicationPCT/US2019/024998, 2019.03.29
(87)International publicationWO 2019/191684, 2019.10.03
Up
/Inventions/details/3773593